ClinicalTrials.gg
TerminatedNCT01296711Updated Apr 14, 2022Results posted

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

A Phase 2 interventional study of CDP6038 (olokizumab) in Rheumatoid Arthritis, sponsored by UCB BIOSCIENCES, Inc.. Terminated at 55 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-14.

Sponsored by UCB BIOSCIENCES, Inc. (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Why this study was terminated
Decision to out-license the compound for further development

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
190
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing olokizumab in Arthritis, Rheumatoid — none open to participants now, none under way, none of them phase 3. olokizumab · Arthritis, Rheumatoid.

Enrollment
6th of 10
190 · median 206
Started
2011
with 1 other
Phase 2
4 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
2 of 10
UCB BIOSCIENCES, Inc.

Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, this one is the 6th largest by enrollment, is one of 2 that started in 2011, is one of 4 in phase 2, and was the 3rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 10 studies testing olokizumab in Arthritis, Rheumatoid is open now. The open studies under Arthritis, Rheumatoid, anywhere →

About olokizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing olokizumab in Arthritis, Rheumatoid as a file.
02

Study summary

The purpose of this study is to evaluate the long term safety and tolerability of CDP6038 (olokizumab) treatment in adult subjects with active rheumatoid arthritis who completed study RA0056 (NCT01242488).

Read the detailed description

Male and female subjects were randomized in a multi-center, open-label, follow-up study to assess the long-term safety and efficacy of a subcutaneous dose of 120 mg CDP6038 (olokizumab), every two weeks, for the treatment of active rheumatoid arthritis.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid arthritis
  • CDP6038
  • Interleukin-6
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject completed the RA0056 study (Week 12 Visit)
  • Subject must have maintained their stable dose (and route) of methotrexate (MTX) between 12.5 to 25mg/week in RA0056, and plan to maintain this same dose and route of administration for at least 12 weeks
  • Female subjects must be either for at least 1 year, surgically incapable of childbearing, or effectively practicing an acceptable method of (either oral/parenteral/implantable hormonal contraceptives, intrauterine device, or barrier and spermicide). Abstinence is not considered an acceptable method of contraception for this study
  • Female subjects of must agree to use 2 methods of adequate contraception during the study and for 6 months (24 weeks) after their last CDP6038 (olokizumab) dose
  • Male subjects must agree to ensure that they or their female partner(s) use adequate contraception during the study and for 12 weeks after the subject receives their last dose of CDP6038 (olokizumab)

Exclusion criteria

Exclusion Criteria:

  • Subject has an ongoing serious adverse event from the RA0056 study
  • Female subject of has a positive pregnancy test at Week 12 in Study RA0056 or plans to become pregnant during the study or within 6 months (24 weeks) following their last dose of study medication
  • Subject has evidence of active or latent tuberculosis
  • Subject is receiving any biologic response modifier or synthetic disease-modifying antirheumatic drug other than MTX
  • Subject has an alcohol consumption of more than 1 unit per weekday. One unit equals 1 glass of beer or lager (\~330mL), a glass of wine (125mL), or a measure of spirits/hard liquor (25mL)
  • Subject with any other condition in RA0056 (eg, laboratory values, frequent adverse events) which in the Investigator's or Sponsor's judgment would make the subject unsuitable for inclusion in the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    CDP6038 (olokizumab)

    Biological: CDP6038 (olokizumab)

Interventions

  • 100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Treatment-emergent Adverse Events (TEAEs)

    Reported TEAEs included adverse events that started or worsened after the first dose of CDP6038 (olokizumab) in Study RA0057 and within 30 days after the last dose.

    Time frame: From Baseline (Week 0 of Study RA0057) until 30 days after the last dose (maximum up to 780 days)

Secondary outcomes

  1. Change From Baseline (Week 0 of Study RA0056) in the Disease Activity Score-28-joint Count (C-reactive Protein) (DAS28[CRP]) to Week 12 of Study RA0057

    DAS28(CRP) was calculated using the tender/painful joint count (TJC) and swollen joint count (SJC) from 28 joints, the Patient's Global Assessment of Disease Activity (PtGADA)-Visual Analog Scale (VAS), andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change in DAS28(CRP) score indicates an improvement in disease activity.

    Time frame: Baseline (Week 0 of Study RA0056) and Week 12 (Study RA0057)

  2. Change From Baseline (Week 0 of Study RA0056) in DAS28(CRP) to Week 24 of Study RA0057

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change in DAS28(CRP) score indicates an improvement in disease activity.

    Time frame: Baseline (Week 0 of Study RA0056) and Week 24 (Study RA0057)

  3. Change From Baseline (Week 0 of Study RA0056) in DAS28(CRP) to Week 48 of Study RA0057

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change in DAS28(CRP) score indicates an improvement in disease activity.

    Time frame: Baseline (Week 0 of Study RA0056) and Week 48 (Study RA0057)

  4. Change From Baseline (Week 0 of Study RA0056) in DAS28(CRP) to Week 96 of Study RA0057

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change in DAS28(CRP) score indicates an improvement in disease activity.

    Time frame: Baseline (Week 0 of Study RA0056) and Week 96 (Study RA0057)

  5. The American College of Rheumatology (ACR) 20% (ACR20) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 12 of Study RA0057

    ACR20 represents at least 20% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, Physician's Global Assessment of Disease Activity (PhGADA)-VAS, Patient's Assessment of Arthritis Pain (PAAP)-VAS, Health Assessment Questionnaire-Disability Index (HAQ-DI) and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0056) up to Week 12 (Study RA0057)

  6. The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 24 of Study RA0057

    ACR20 represents at least 20% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0056) up to Week 24 (Study RA0057)

  7. The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 48 of Study RA0057

    ACR20 represents at least 20% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0056) up to Week 48 (Study RA0057)

  8. The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 96 of Study RA0057

    ACR20 represents at least 20% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0056) up to Week 96 (Study RA0057)

  9. The ACR 50% (ACR50) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 12 of Study RA0057

    ACR50 represents at least 50% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0056) up to Week 12 (Study RA0057)

  10. The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 24 of Study RA0057

    ACR50 represents at least 50% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0056) up to Week 24 (Study RA0057)

  11. The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 48 of Study RA0057

    ACR50 represents at least 50% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0056) up to Week 48 (Study RA0057)

  12. The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 96 of Study RA0057

    ACR50 represents at least 50% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0056) up to Week 96 (Study RA0057)

  13. The ACR 70% (ACR70) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 12 of Study RA0057

    ACR70 represents at least 70% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0056) up to Week 12 (Study RA0057)

  14. The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 24 of Study RA0057

    ACR70 represents at least 70% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0056) up to Week 24 (Study RA0057)

  15. The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 48 of Study RA0057

    ACR70 represents at least 70% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0056) up to Week 48 (Study RA0057)

  16. The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 96 of Study RA0057

    ACR70 represents at least 70% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0056) up to Week 96 (Study RA0057)

  17. Percentage of Subjects With DAS28(CRP) <2.6 at Week 12 of Study RA0057

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than 2.6 implies remission.

    Time frame: Week 12 (Study RA0057)

  18. Percentage of Subjects With DAS28(CRP) <2.6 at Week 24 of Study RA0057

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than 2.6 implies remission.

    Time frame: Week 24 (Study RA0057)

  19. Percentage of Subjects With DAS28(CRP) <2.6 at Week 48 of Study RA0057

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than 2.6 implies remission.

    Time frame: Week 48 (Study RA0057)

  20. Percentage of Subjects With DAS28(CRP) <2.6 at Week 96 of Study RA0057

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than 2.6 implies remission.

    Time frame: Week 96 (Study RA0057)

  21. Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 12 of Study RA0057

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than or equal to (\<=) 3.2 implies low disease activity.

    Time frame: Week 12 (Study RA0057)

  22. Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 24 of Study RA0057

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score \<=3.2 implies low disease activity.

    Time frame: Week 24 (Study RA0057)

  23. Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 48 of Study RA0057

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score \<=3.2 implies low disease activity.

    Time frame: Week 48 (Study RA0057)

  24. Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 96 of Study RA0057

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score \<=3.2 implies low disease activity.

    Time frame: Week 96 (Study RA0057)

  25. Change From Baseline (Week 0 of Study RA0056) in the Clinical Disease Activity Index (CDAI) to Week 48 of Study RA0057

    CDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS and PhGADA-VAS, according to the following formula: SJC + TJC + PtGADA + PhGADA Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Total score range is from 0-100, with the high scores representing high disease activity. A negative change in CDAI score indicates an improvement in disease activity.

    Time frame: Baseline (Week 0 of Study RA0056) and Week 48 (Study RA0057)

  26. Change From Baseline (Week 0 of Study RA0056) in the CDAI to Week 96 of Study RA0057

    CDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS and PhGADA-VAS, according to the following formula: SJC + TJC + PtGADA + PhGADA Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Total score range is from 0-100, with the high scores representing high disease activity. A negative change in CDAI score indicates an improvement in disease activity.

    Time frame: Baseline (Week 0 of Study RA0056) and Week 96 (Study RA0057)

  27. Change From Baseline (Week 0 of Study RA0056) in the Simplified Disease Activity Index (SDAI) to Week 48 of Study RA0057

    SDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS, PhGADA-VAS and CRP (in milligrams per decilitre \[mg/dL\]), according to the following formula: SJC + TJC + PtGADA + PhGADA + CRP (mg/dL) Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). • CRP range was from 0 to 10 mg/dL. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. A negative change in SDAI score indicates an improvement in disease activity.

    Time frame: Baseline (Week 0 of Study RA0056) and Week 48 (Study RA0057)

  28. Change From Baseline (Week 0 of Study RA0056) in the SDAI to Week 96 of Study RA0057

    SDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS, PhGADA-VAS and CRP (in milligrams per decilitre \[mg/dL\]), according to the following formula: SJC + TJC + PtGADA + PhGADA + CRP (mg/dL) Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). • CRP range was from 0 to 10 mg/dL. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. A negative change in SDAI score indicates an improvement in disease activity.

    Time frame: Baseline (Week 0 of Study RA0056) and Week 96 (Study RA0057)

07

Results

Posted Apr 14, 2022
Limitations and caveats
The clinical trial was terminated early as a result of a strategic UCB decision to out-license the study drug for further development. As a result, only small numbers of subjects were still in the study past the Week 48 time point.

Participant flow

The present study was an open-label extension to study RA0056 (NCT01242488). Subjects completing the 12-week treatment period of study RA0056 had the opportunity to participate in this study. First subject enrolled: 07 March 2011. Early termination: 05 Aug 2013.

Participant flow — Overall Study
MilestoneRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Started2020212017164036
Completed4128775915
Not completed168131310113121
Withdrew: Adverse event314316113
Withdrew: Lack of efficacy14111023
Withdrew: Lost to follow-up00112042
Withdrew: Protocol violation00011000
Withdrew: Withdrawal by subject42211121
Withdrew: Study termination815444810
Withdrew: Continued elevated liver enzymes00010000
Withdrew: Methotrexate discontinued00010000
Withdrew: Investigator discretion00000010
Withdrew: Other00000010
Withdrew: Required restricted steroid injections00000010
Withdrew: Ongoing missed appointments00000010
Withdrew: Failure to comply with visits00000001
Withdrew: Patient decision due to transport00000001

Outcome measures

PrimaryNumber of Subjects With Treatment-emergent Adverse Events (TEAEs)

Reported TEAEs included adverse events that started or worsened after the first dose of CDP6038 (olokizumab) in Study RA0057 and within 30 days after the last dose.

Time frame:
From Baseline (Week 0 of Study RA0057) until 30 days after the last dose (maximum up to 780 days)
Reported as:
Count of participants · Participants
Number of Subjects With Treatment-emergent Adverse Events (TEAEs)
ParticipantsRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Number of Subjects With Treatment-emergent Adverse Events (TEAEs)1720191815153935
SecondaryChange From Baseline (Week 0 of Study RA0056) in the Disease Activity Score-28-joint Count (C-reactive Protein) (DAS28[CRP]) to Week 12 of Study RA0057

DAS28(CRP) was calculated using the tender/painful joint count (TJC) and swollen joint count (SJC) from 28 joints, the Patient's Global Assessment of Disease Activity (PtGADA)-Visual Analog Scale (VAS), andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change in DAS28(CRP) score indicates an improvement in disease activity.

Time frame:
Baseline (Week 0 of Study RA0056) and Week 12 (Study RA0057)
Reported as:
Mean · units on a scale
Change From Baseline (Week 0 of Study RA0056) in the Disease Activity Score-28-joint Count (C-reactive Protein) (DAS28[CRP]) to Week 12 of Study RA0057
units on a scaleRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Change From Baseline (Week 0 of Study RA0056) in the Disease Activity Score-28-joint Count (C-reactive Protein) (DAS28[CRP]) to Week 12 of Study RA0057-2.2809 ± 1.45737-2.2485 ± 1.39384-2.5123 ± 1.39667-2.2230 ± 1.17572-1.6957 ± 0.67335-2.1735 ± 1.56606-2.3727 ± 1.41421-2.4710 ± 1.43947
SecondaryChange From Baseline (Week 0 of Study RA0056) in DAS28(CRP) to Week 24 of Study RA0057

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change in DAS28(CRP) score indicates an improvement in disease activity.

Time frame:
Baseline (Week 0 of Study RA0056) and Week 24 (Study RA0057)
Reported as:
Mean · units on a scale
Change From Baseline (Week 0 of Study RA0056) in DAS28(CRP) to Week 24 of Study RA0057
units on a scaleRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Change From Baseline (Week 0 of Study RA0056) in DAS28(CRP) to Week 24 of Study RA0057-2.6441 ± 1.465661.46566 ± 1.17637-2.5811 ± 1.40191-2.5999 ± 1.16812-1.7189 ± 0.87218-2.4221 ± 1.37341-2.1484 ± 1.34676-2.7624 ± 1.47841
SecondaryChange From Baseline (Week 0 of Study RA0056) in DAS28(CRP) to Week 48 of Study RA0057

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change in DAS28(CRP) score indicates an improvement in disease activity.

Time frame:
Baseline (Week 0 of Study RA0056) and Week 48 (Study RA0057)
Reported as:
Mean · units on a scale
Change From Baseline (Week 0 of Study RA0056) in DAS28(CRP) to Week 48 of Study RA0057
units on a scaleRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Change From Baseline (Week 0 of Study RA0056) in DAS28(CRP) to Week 48 of Study RA0057-2.3257 ± 1.07427-2.2498 ± 1.66580-2.5277 ± 1.56763-2.7050 ± 0.96160-2.3824 ± 0.79065-2.1501 ± 0.64141-2.2403 ± 1.47765-2.7611 ± 1.31329
SecondaryChange From Baseline (Week 0 of Study RA0056) in DAS28(CRP) to Week 96 of Study RA0057

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change in DAS28(CRP) score indicates an improvement in disease activity.

Time frame:
Baseline (Week 0 of Study RA0056) and Week 96 (Study RA0057)
Reported as:
Mean · units on a scale
Change From Baseline (Week 0 of Study RA0056) in DAS28(CRP) to Week 96 of Study RA0057
units on a scaleRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Change From Baseline (Week 0 of Study RA0056) in DAS28(CRP) to Week 96 of Study RA0057-3.2427 ± 1.74642-3.5767-2.5985 ± 2.16200-3.0999 ± 0.02877-1.7516 ± 2.03992-2.6451 ± 0.96108-3.3173 ± 3.23508-3.7982 ± 1.23889
SecondaryThe American College of Rheumatology (ACR) 20% (ACR20) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 12 of Study RA0057

ACR20 represents at least 20% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, Physician's Global Assessment of Disease Activity (PhGADA)-VAS, Patient's Assessment of Arthritis Pain (PAAP)-VAS, Health Assessment Questionnaire-Disability Index (HAQ-DI) and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0056) up to Week 12 (Study RA0057)
Reported as:
Number · Percentage of responders
The American College of Rheumatology (ACR) 20% (ACR20) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 12 of Study RA0057
Percentage of respondersRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
The American College of Rheumatology (ACR) 20% (ACR20) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 12 of Study RA005740.050.076.235.058.850.047.552.8
SecondaryThe ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 24 of Study RA0057

ACR20 represents at least 20% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0056) up to Week 24 (Study RA0057)
Reported as:
Number · Percentage of responders
The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 24 of Study RA0057
Percentage of respondersRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 24 of Study RA005740.050.066.730.047.162.542.563.9
SecondaryThe ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 48 of Study RA0057

ACR20 represents at least 20% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0056) up to Week 48 (Study RA0057)
Reported as:
Number · Percentage of responders
The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 48 of Study RA0057
Percentage of respondersRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 48 of Study RA005740.030.042.935.047.143.825.050.0
SecondaryThe ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 96 of Study RA0057

ACR20 represents at least 20% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0056) up to Week 96 (Study RA0057)
Reported as:
Number · Percentage of responders
The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 96 of Study RA0057
Percentage of respondersRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 96 of Study RA005715.05.09.55.011.812.52.513.9
SecondaryThe ACR 50% (ACR50) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 12 of Study RA0057

ACR50 represents at least 50% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0056) up to Week 12 (Study RA0057)
Reported as:
Number · Percentage of responders
The ACR 50% (ACR50) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 12 of Study RA0057
Percentage of respondersRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
The ACR 50% (ACR50) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 12 of Study RA005725.015.033.315.017.618.827.538.9
SecondaryThe ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 24 of Study RA0057

ACR50 represents at least 50% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0056) up to Week 24 (Study RA0057)
Reported as:
Number · Percentage of responders
The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 24 of Study RA0057
Percentage of respondersRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 24 of Study RA005720.020.033.315.011.843.825.041.7
SecondaryThe ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 48 of Study RA0057

ACR50 represents at least 50% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0056) up to Week 48 (Study RA0057)
Reported as:
Number · Percentage of responders
The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 48 of Study RA0057
Percentage of respondersRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 48 of Study RA005710.015.028.620.035.331.315.033.3
SecondaryThe ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 96 of Study RA0057

ACR50 represents at least 50% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0056) up to Week 96 (Study RA0057)
Reported as:
Number · Percentage of responders
The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 96 of Study RA0057
Percentage of respondersRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 96 of Study RA005710.05.04.80.011.86.32.58.3
SecondaryThe ACR 70% (ACR70) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 12 of Study RA0057

ACR70 represents at least 70% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0056) up to Week 12 (Study RA0057)
Reported as:
Number · Percentage of responders
The ACR 70% (ACR70) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 12 of Study RA0057
Percentage of respondersRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
The ACR 70% (ACR70) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 12 of Study RA005710.05.019.05.00.018.815.013.9
SecondaryThe ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 24 of Study RA0057

ACR70 represents at least 70% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0056) up to Week 24 (Study RA0057)
Reported as:
Number · Percentage of responders
The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 24 of Study RA0057
Percentage of respondersRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 24 of Study RA005710.015.019.05.00.012.510.025.0
SecondaryThe ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 48 of Study RA0057

ACR70 represents at least 70% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0056) up to Week 48 (Study RA0057)
Reported as:
Number · Percentage of responders
The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 48 of Study RA0057
Percentage of respondersRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 48 of Study RA00575.05.023.810.011.86.310.013.9
SecondaryThe ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 96 of Study RA0057

ACR70 represents at least 70% improvement from Baseline for each of TJC (68 joints) + SJC (66 joints) + at least 3 components of 5 for: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), its score (0-3) computed from item scores, with lower scores indicates less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0056) up to Week 96 (Study RA0057)
Reported as:
Number · Percentage of responders
The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 96 of Study RA0057
Percentage of respondersRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0056) to Week 96 of Study RA00575.00.04.80.05.90.02.55.6
SecondaryPercentage of Subjects With DAS28(CRP) <2.6 at Week 12 of Study RA0057

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than 2.6 implies remission.

Time frame:
Week 12 (Study RA0057)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With DAS28(CRP) <2.6 at Week 12 of Study RA0057
Percentage of subjectsRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Percentage of Subjects With DAS28(CRP) <2.6 at Week 12 of Study RA005725.030.038.125.0018.825.025.0
SecondaryPercentage of Subjects With DAS28(CRP) <2.6 at Week 24 of Study RA0057

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than 2.6 implies remission.

Time frame:
Week 24 (Study RA0057)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With DAS28(CRP) <2.6 at Week 24 of Study RA0057
Percentage of subjectsRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Percentage of Subjects With DAS28(CRP) <2.6 at Week 24 of Study RA005725.035.033.325.017.612.520.033.3
SecondaryPercentage of Subjects With DAS28(CRP) <2.6 at Week 48 of Study RA0057

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than 2.6 implies remission.

Time frame:
Week 48 (Study RA0057)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With DAS28(CRP) <2.6 at Week 48 of Study RA0057
Percentage of subjectsRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Percentage of Subjects With DAS28(CRP) <2.6 at Week 48 of Study RA005720.030.023.820.029.412.515.022.2
SecondaryPercentage of Subjects With DAS28(CRP) <2.6 at Week 96 of Study RA0057

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than 2.6 implies remission.

Time frame:
Week 96 (Study RA0057)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With DAS28(CRP) <2.6 at Week 96 of Study RA0057
Percentage of subjectsRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Percentage of Subjects With DAS28(CRP) <2.6 at Week 96 of Study RA005710.05.09.55.011.802.58.3
SecondaryPercentage of Subjects With DAS28(CRP) ≤3.2 at Week 12 of Study RA0057

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score less than or equal to (\<=) 3.2 implies low disease activity.

Time frame:
Week 12 (Study RA0057)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 12 of Study RA0057
Percentage of subjectsRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 12 of Study RA005735.640.052.430.017.625.035.044.4
SecondaryPercentage of Subjects With DAS28(CRP) ≤3.2 at Week 24 of Study RA0057

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score \<=3.2 implies low disease activity.

Time frame:
Week 24 (Study RA0057)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 24 of Study RA0057
Percentage of subjectsRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 24 of Study RA005735.040.038.130.023.537.535.050.0
SecondaryPercentage of Subjects With DAS28(CRP) ≤3.2 at Week 48 of Study RA0057

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score \<=3.2 implies low disease activity.

Time frame:
Week 48 (Study RA0057)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 48 of Study RA0057
Percentage of subjectsRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 48 of Study RA005725.045.023.825.029.418.822.547.2
SecondaryPercentage of Subjects With DAS28(CRP) ≤3.2 at Week 96 of Study RA0057

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, and CRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Scores on the DAS28(CRP) range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28(CRP) score \<=3.2 implies low disease activity.

Time frame:
Week 96 (Study RA0057)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 96 of Study RA0057
Percentage of subjectsRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 96 of Study RA005715.05.09.55.011.802.511.1
SecondaryChange From Baseline (Week 0 of Study RA0056) in the Clinical Disease Activity Index (CDAI) to Week 48 of Study RA0057

CDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS and PhGADA-VAS, according to the following formula: SJC + TJC + PtGADA + PhGADA Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Total score range is from 0-100, with the high scores representing high disease activity. A negative change in CDAI score indicates an improvement in disease activity.

Time frame:
Baseline (Week 0 of Study RA0056) and Week 48 (Study RA0057)
Reported as:
Mean · units on a scale
Change From Baseline (Week 0 of Study RA0056) in the Clinical Disease Activity Index (CDAI) to Week 48 of Study RA0057
units on a scaleRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Change From Baseline (Week 0 of Study RA0056) in the Clinical Disease Activity Index (CDAI) to Week 48 of Study RA0057-80.1000 ± 53.28425-65.3373 ± 63.72098-94.3335 ± 61.48562-80.8077 ± 57.91606-79.9231 ± 30.09849-84.8378 ± 33.77586-74.3315 ± 53.99274-83.4950 ± 42.48396
SecondaryChange From Baseline (Week 0 of Study RA0056) in the CDAI to Week 96 of Study RA0057

CDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS and PhGADA-VAS, according to the following formula: SJC + TJC + PtGADA + PhGADA Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. Total score range is from 0-100, with the high scores representing high disease activity. A negative change in CDAI score indicates an improvement in disease activity.

Time frame:
Baseline (Week 0 of Study RA0056) and Week 96 (Study RA0057)
Reported as:
Mean · units on a scale
Change From Baseline (Week 0 of Study RA0056) in the CDAI to Week 96 of Study RA0057
units on a scaleRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Change From Baseline (Week 0 of Study RA0056) in the CDAI to Week 96 of Study RA0057-108.0000 ± 66.77574-118.0000-89.0000 ± 55.97321-74.3846 ± 4.78657-74.0000 ± 55.74944-90.5000 ± 13.43503-104.5000 ± 126.57211-107.4000 ± 51.52960
SecondaryChange From Baseline (Week 0 of Study RA0056) in the Simplified Disease Activity Index (SDAI) to Week 48 of Study RA0057

SDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS, PhGADA-VAS and CRP (in milligrams per decilitre \[mg/dL\]), according to the following formula: SJC + TJC + PtGADA + PhGADA + CRP (mg/dL) Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). • CRP range was from 0 to 10 mg/dL. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. A negative change in SDAI score indicates an improvement in disease activity.

Time frame:
Baseline (Week 0 of Study RA0056) and Week 48 (Study RA0057)
Reported as:
Mean · units on a scale
Change From Baseline (Week 0 of Study RA0056) in the Simplified Disease Activity Index (SDAI) to Week 48 of Study RA0057
units on a scaleRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Change From Baseline (Week 0 of Study RA0056) in the Simplified Disease Activity Index (SDAI) to Week 48 of Study RA0057-92.1000 ± 62.22799-75.8757 ± 74.37825-104.6668 ± 80.47988-92.4077 ± 55.42723-87.7564 ± 28.41084-112.5378 ± 52.99896-87.5815 ± 59.26016-107.4080 ± 60.17362
SecondaryChange From Baseline (Week 0 of Study RA0056) in the SDAI to Week 96 of Study RA0057

SDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS, PhGADA-VAS and CRP (in milligrams per decilitre \[mg/dL\]), according to the following formula: SJC + TJC + PtGADA + PhGADA + CRP (mg/dL) Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). • CRP range was from 0 to 10 mg/dL. The 28 joints included the shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of the hands; and the knees. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. A negative change in SDAI score indicates an improvement in disease activity.

Time frame:
Baseline (Week 0 of Study RA0056) and Week 96 (Study RA0057)
Reported as:
Mean · units on a scale
Change From Baseline (Week 0 of Study RA0056) in the SDAI to Week 96 of Study RA0057
units on a scaleRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Change From Baseline (Week 0 of Study RA0056) in the SDAI to Week 96 of Study RA0057-111.0000 ± 68.78953-125.0000-90.3333 ± 56.04760-91.8846 ± 29.53531-75.3333 ± 56.09219-147.5000 ± 77.07464-128.0000 ± 147.07821-143.4000 ± 80.28574

Adverse events

Collected over From Baseline (Week 0 of Study RA0057) until 30 days after the last dose (maximum up to 780 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RA0056 CDP6038 (Olokizumab) 120 mg q2w0/20 (0%)3/20 (15%)16/20 (80%)
RA0056 CDP6038 (Olokizumab) 120 mg q4w0/20 (0%)6/20 (30%)20/20 (100%)
RA0056 CDP6038 (Olokizumab) 240 mg q2w0/21 (0%)6/21 (28.6%)18/21 (85.7%)
RA0056 CDP6038 (Olokizumab) 240 mg q4w0/20 (0%)7/20 (35%)17/20 (85%)
RA0056 CDP6038 (Olokizumab) 60 mg q2w0/17 (0%)5/17 (29.4%)15/17 (88.2%)
RA0056 CDP6038 (Olokizumab) 60 mg q4w1/16 (6.3%)3/16 (18.8%)15/16 (93.8%)
RA0056 Placebo1/40 (2.5%)14/40 (35%)36/40 (90%)
RA0056 Tocilizumab 8 mg/kg q4w0/36 (0%)4/36 (11.1%)35/36 (97.2%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Chest painGeneral disorders0/201/200/212/200/170/161/400/36
PneumoniaInfections and infestations0/200/200/211/200/171/160/400/36
Road traffic accidentInjury, poisoning and procedural complications0/200/200/210/200/171/160/400/36
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/200/200/210/200/171/160/400/36
EmphysemaRespiratory, thoracic and mediastinal disorders0/200/200/210/200/171/160/400/36
Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders0/200/200/210/200/171/160/400/36
Musculoskeletal painMusculoskeletal and connective tissue disorders0/200/200/210/200/171/160/400/36
CellulitisInfections and infestations1/200/200/210/201/170/161/400/36
ArthralgiaMusculoskeletal and connective tissue disorders0/200/200/211/201/170/160/400/36
CholecystectomySurgical and medical procedures0/200/200/210/201/170/160/400/36
Most frequent other events
Showing 10 of 136
Most frequent other events
EventRA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4w
Upper respiratory tract infectionInfections and infestations3/203/209/212/204/173/167/405/36
NasopharyngitisInfections and infestations1/206/200/211/202/172/163/403/36
HeadacheNervous system disorders1/206/201/211/201/170/161/404/36
Urinary tract infectionInfections and infestations2/201/206/212/202/173/165/405/36
Back painMusculoskeletal and connective tissue disorders0/205/202/212/200/170/167/404/36
CoughRespiratory, thoracic and mediastinal disorders0/204/203/212/201/174/166/405/36
RashSkin and subcutaneous tissue disorders5/201/202/210/201/171/161/403/36
Injection site reactionGeneral disorders2/202/200/211/202/170/166/408/36
BronchitisInfections and infestations1/202/203/213/201/173/165/403/36
Rheumatoid arthritisMusculoskeletal and connective tissue disorders3/202/201/213/201/173/163/404/36

Baseline characteristics

Safety Population included all enrolled subjects who received at least 1 injection of CDP6038 (olokizumab) in Study RA0057.

Age, Customized
Age, Customized(Participants)RA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4wTotal
<=18 years000000000
Between 18 and 65 years1716171413142729147
>=65 years34464213743
Sex: Female, Male
Sex: Female, Male(Participants)RA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4wTotal
Female1717191614143331161
Male3324327529
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RA0056 CDP6038 (Olokizumab) 120 mg q2wRA0056 CDP6038 (Olokizumab) 120 mg q4wRA0056 CDP6038 (Olokizumab) 240 mg q2wRA0056 CDP6038 (Olokizumab) 240 mg q4wRA0056 CDP6038 (Olokizumab) 60 mg q2wRA0056 CDP6038 (Olokizumab) 60 mg q4wRA0056 PlaceboRA0056 Tocilizumab 8 mg/kg q4wTotal
American Indian or Alaska Native000000000
Asian000000000
Native Hawaiian or Other Pacific Islander000000000
Black or African American1132143419
White1918181816123531167
More than one race000000000
Unknown or Not Reported010000214
08

Study locations

55 sites
  • 166
    Mesa, Arizona, United States
  • 154
    Phoenix, Arizona, United States
  • 118
    Scottsdale, Arizona, United States
  • 103
    Hot Springs, Arkansas, United States
  • 127
    Covina, California, United States
  • 148
    La Jolla, California, United States
  • 184
    Long Beach, California, United States
  • 177
    Los Angeles, California, United States
  • 104
    Palo Alto, California, United States
  • 129
    Santa Maria, California, United States
  • 164
    Upland, California, United States
  • 141
    Hamden, Connecticut, United States
  • 111
    Lewes, Delaware, United States
  • 151
    DeBary, Florida, United States
  • 114
    Jupiter, Florida, United States
  • 157
    Tampa, Florida, United States
  • 183
    Tampa, Florida, United States
  • 116
    Idaho Falls, Idaho, United States
  • 160
    Moline, Illinois, United States
  • 168
    Springfield, Illinois, United States
  • 133
    Cedar Rapids, Iowa, United States
  • 172
    Kansas City, Kansas, United States
  • 185
    Saint Clair Shores, Michigan, United States
  • 112
    Saint Louis, Missouri, United States
  • 134
    Saint Louis, Missouri, United States
  • 102
    Lincoln, Nebraska, United States
  • 171
    Freehold, New Jersey, United States
  • 152
    Toms River, New Jersey, United States
  • 174
    Brooklyn, New York, United States
  • 170
    Charlotte, North Carolina, United States
  • 150
    Cincinnati, Ohio, United States
  • 100
    Dayton, Ohio, United States
  • 110
    Oklahoma City, Oklahoma, United States
  • 165
    Duncansville, Pennsylvania, United States
  • 105
    Nashville, Tennessee, United States
  • 135
    Austin, Texas, United States
  • 128
    Dallas, Texas, United States
  • 126
    Houston, Texas, United States
  • 132
    Houston, Texas, United States
  • 138
    Houston, Texas, United States
  • 181
    Houston, Texas, United States
  • 145
    Mesquite, Texas, United States
  • 143
    Nassau Bay, Texas, United States
  • 122
    San Antonio, Texas, United States
  • 144
    Tomball, Texas, United States
  • 142
    Victoria, Texas, United States
  • 139
    Chesapeake, Virginia, United States
  • 175
    Tacoma, Washington, United States
  • 136
    Beckley, West Virginia, United States
  • 167
    Clarksburg, West Virginia, United States
  • 401
    Brussels, Belgium
  • 400
    Liege, Belgium
  • 206
    Essex, United Kingdom
  • 208
    Southampton, United Kingdom
  • 209
    Torquay, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2011 to primary completion in May 2013, 25 months.

Results were first posted in Apr 2022, 8 years 11 months after primary completion. A results delay was requested in Jun 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2011
First posted
Feb 15, 2011
StartActual
Mar 7, 2011
Primary completionActual
May 1, 2013
CompletionActual
Aug 5, 2013
Results delay requested
Jun 3, 2013
Results first posted
Apr 14, 2022
Last update
Apr 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01296711
Collaborators
R-Pharm
Responsible party
Sponsor
First posted
Feb 15, 2011
Start date
Mar 7, 2011
Primary completion
May 1, 2013
Completion
Aug 5, 2013
Results posted
Apr 14, 2022
Last update
Apr 14, 2022

Study contacts

Mark Genovese, Dr
principal investigator · Stanford University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olokizumab

Start the discussion